Literature DB >> 27066584

White matter lesions in FTLD: distinct phenotypes characterize GRN and C9ORF72 mutations.

Fatima Ameur1, Olivier Colliot1, Paola Caroppo1, Sebastian Ströer1, Didier Dormont1, Alexis Brice1, Carole Azuar1, Bruno Dubois1, Isabelle Le Ber1, Anne Bertrand1.   

Abstract

Frontotemporal lobar degeneration (FTLD) has a high frequency of genetic forms; the 2 most common are GRN (progranulin) and C9ORF72 mutations. Recently, our group reported extensive white matter (WM) lesions in 4 patients with FTLD caused by GRN mutation, in the absence of noteworthy cardiovascular risk factors,(1) in line with other studies in GRN mutation carriers.(2,3) Here we compared the characteristics of frontal WM lesions in patients with behavioral variant of FTLD (bv-FTLD) caused by GRN and C9ORF72 mutations.

Entities:  

Year:  2016        PMID: 27066584      PMCID: PMC4817905          DOI: 10.1212/NXG.0000000000000047

Source DB:  PubMed          Journal:  Neurol Genet        ISSN: 2376-7839


Frontotemporal lobar degeneration (FTLD) has a high frequency of genetic forms; the 2 most common are GRN (progranulin) and C9ORF72 mutations. Recently, our group reported extensive white matter (WM) lesions in 4 patients with FTLD caused by GRN mutation, in the absence of noteworthy cardiovascular risk factors,[1] in line with other studies in GRN mutation carriers.[2,3] Here we compared the characteristics of frontal WM lesions in patients with behavioral variant of FTLD (bv-FTLD) caused by GRN and C9ORF72 mutations.

Methods.

Patients.

We retrospectively collected clinical and MRI data from 28 patients with a diagnosis of bv-FTLD based on the Rascovsky criteria,[4] including 11 GRN mutation carriers and 17 C9ORF72 mutation carriers. One patient with multiple cardiovascular risk factors was excluded from this study; all other patients had no cardiovascular risk factors apart from sex, age, or treated and well-controlled hypertension. Age at onset was determined as the time of symptom appearance reported by the closest relative of the patient. A group of 11 age-matched healthy individuals were used as controls. Two GRN patients have been reported in a previous publication.[1] This retrospective study was approved by our institutional review board. Informed consent was obtained according to the French legislation for clinical genetic studies.

MRI.

All patients had a brain MRI including fluid-attenuated inversion recovery (FLAIR) sequence (1.5T/3T, echo time >100 ms, slice thickness ≤5 mm). One neuroradiologist (F.A.) assessed the severity of left and right frontal atrophy using the Kipps-Davis scale for frontal atrophy.[5] Three neuroradiologists (F.A., S.S., and A. Bertrand) and 1 neurologist (P.C.) characterized the severity of WM lesions on FLAIR images in the left and right frontal lobes using an ad hoc 3-level visual score (figure). All readers were blinded to clinical and genetic data.
Figure

Visual score for the characterization of frontal WM lesions on FLAIR images

(A) Grade A: minor fluid-attenuated inversion recovery (FLAIR) hyperintensities, <4 mm thick, limited to the periventricular area, no extension into the deep and subcortical white matter (WM). Grade B: moderate FLAIR hyperintensities, <6 mm thick, affecting the periventricular and deep WM, no extension into the subcortical WM. Grade C: marked FLAIR hyperintensities, >6 mm thick, affecting periventricular, deep, and subcortical WM. (B) Frontal WM lesions were significantly different between groups on the left side (p < 0.0001, Kruskal-Wallis test) and on the right side (p = 0.007, Kruskal-Wallis test). Dunn post hoc tests showed statistically significant differences between the GRN group and controls and between the GRN group and the C9ORF72 group for the left and right side.

Visual score for the characterization of frontal WM lesions on FLAIR images

(A) Grade A: minor fluid-attenuated inversion recovery (FLAIR) hyperintensities, <4 mm thick, limited to the periventricular area, no extension into the deep and subcortical white matter (WM). Grade B: moderate FLAIR hyperintensities, <6 mm thick, affecting the periventricular and deep WM, no extension into the subcortical WM. Grade C: marked FLAIR hyperintensities, >6 mm thick, affecting periventricular, deep, and subcortical WM. (B) Frontal WM lesions were significantly different between groups on the left side (p < 0.0001, Kruskal-Wallis test) and on the right side (p = 0.007, Kruskal-Wallis test). Dunn post hoc tests showed statistically significant differences between the GRN group and controls and between the GRN group and the C9ORF72 group for the left and right side. Statistical analysis was performed using GraphPad Prism 5.0 (San Diego, CA). Interrater agreements were assessed using the weighted κ test. Comparisons of sex and symptoms between the 3 groups were assessed using the χ2 test; other comparisons were assessed using the Kruskal-Wallis test and Dunn post hoc test (when comparing 3 groups) or the Mann-Whitney test (when comparing 2 groups).

Results.

No significant difference was observed between groups regarding sex, age at onset, age at MRI, disease duration, and associated amyotrophic lateral sclerosis symptoms (table e-1 at Neurology.org/ng). Interrater agreement between the 4 readers for the characterization of WM lesions was moderate to very strong (κ = 0.536–0.805, median 0.74). Frontal WM lesions were different between the 3 groups (p = 0.007 for the right side and p < 0.0001 for the left side, Kruskal-Wallis test). The grade of WM lesions was higher on both sides in the GRN group than in the control group and the C9ORF72 group (Dunn post hoc test) (figure). In GRN mutation carriers, the presence of grade C WM lesions on the left side was associated with a higher degree of left frontal atrophy (p = 0.003, Mann-Whitney test) but not with longer disease duration (p = 0.082, Mann-Whitney test). No significant result was observed for the right side, where WM lesions were less frequent.

Discussion.

Previous reports have shown that some FTLD cases with GRN mutation present with marked FLAIR hyperintensities in the WM.[1-3,6] Here we extended these findings by showing that these WM lesions are frequent: 45% (5/11) of GRN mutation carriers had extensive frontal WM lesions (grade C) in the absence of noteworthy cardiovascular risk factors. These WM lesions were atypical for common cerebral small vessel disease because they extended toward the subcortical WM (figure) and were associated with a higher degree of left frontal atrophy. They were not associated with longer disease duration; thus, they may be a consequence of a faster atrophy process than in the other patients. Of note, the patient excluded from the study because of cardiovascular risk factors had only grade A WM lesions in the frontal lobes. It is interesting that both GRN and C9ORF72 mutation carriers are likely to have underlying FTLD-TDP43 pathology. This suggests that gene effects can exceed lesion effects in the phenotypical expression of FTLD. The progranulin protein is normally expressed not only in neurons but also in activated microglia, astrocytes, and oligodendroglia and plays a role in inflammation.[7] Histopathologic studies of the WM in GRN mutation carriers have reported microglial activation in the areas of abnormal WM on MRI.[2] These results favor the hypothesis of a specific vulnerability of the WM to granulin haploinsufficiency.
  7 in total

1.  Prominent phenotypic variability associated with mutations in Progranulin.

Authors:  Brendan J Kelley; Wael Haidar; Bradley F Boeve; Matt Baker; Neill R Graff-Radford; Thomas Krefft; Andrew R Frank; Clifford R Jack; Maria Shiung; David S Knopman; Keith A Josephs; Sotirios A Parashos; Rosa Rademakers; Mike Hutton; Stuart Pickering-Brown; Jennifer Adamson; Karen M Kuntz; Dennis W Dickson; Joseph E Parisi; Glenn E Smith; Robert J Ivnik; Ronald C Petersen
Journal:  Neurobiol Aging       Date:  2007-10-18       Impact factor: 4.673

2.  Extensive white matter involvement in patients with frontotemporal lobar degeneration: think progranulin.

Authors:  Paola Caroppo; Isabelle Le Ber; Agnès Camuzat; Fabienne Clot; Lionel Naccache; Foudil Lamari; Anne De Septenville; Anne Bertrand; Serge Belliard; Didier Hannequin; Olivier Colliot; Alexis Brice
Journal:  JAMA Neurol       Date:  2014-12       Impact factor: 18.302

3.  Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred.

Authors:  Anna M Pietroboni; Giorgio G Fumagalli; Laura Ghezzi; Chiara Fenoglio; Francesca Cortini; Maria Serpente; Claudia Cantoni; Emanuela Rotondo; Priscilla Corti; Miryam Carecchio; Mariateresa Bassi; Nereo Bresolin; Domenico Galbiati; Daniela Galimberti; Elio Scarpini
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 4.  Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia.

Authors:  John C van Swieten; Peter Heutink
Journal:  Lancet Neurol       Date:  2008-09-02       Impact factor: 44.182

Review 5.  Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration.

Authors:  Basar Cenik; Chantelle F Sephton; Bercin Kutluk Cenik; Joachim Herz; Gang Yu
Journal:  J Biol Chem       Date:  2012-08-02       Impact factor: 5.157

6.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.

Authors:  Katya Rascovsky; John R Hodges; David Knopman; Mario F Mendez; Joel H Kramer; John Neuhaus; John C van Swieten; Harro Seelaar; Elise G P Dopper; Chiadi U Onyike; Argye E Hillis; Keith A Josephs; Bradley F Boeve; Andrew Kertesz; William W Seeley; Katherine P Rankin; Julene K Johnson; Maria-Luisa Gorno-Tempini; Howard Rosen; Caroline E Prioleau-Latham; Albert Lee; Christopher M Kipps; Patricia Lillo; Olivier Piguet; Jonathan D Rohrer; Martin N Rossor; Jason D Warren; Nick C Fox; Douglas Galasko; David P Salmon; Sandra E Black; Marsel Mesulam; Sandra Weintraub; Brad C Dickerson; Janine Diehl-Schmid; Florence Pasquier; Vincent Deramecourt; Florence Lebert; Yolande Pijnenburg; Tiffany W Chow; Facundo Manes; Jordan Grafman; Stefano F Cappa; Morris Freedman; Murray Grossman; Bruce L Miller
Journal:  Brain       Date:  2011-08-02       Impact factor: 13.501

7.  Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale.

Authors:  Christopher M Kipps; R Rhys Davies; Joanna Mitchell; Jillian J Kril; Glenda M Halliday; John R Hodges
Journal:  Dement Geriatr Cogn Disord       Date:  2007-03-19       Impact factor: 2.959

  7 in total
  10 in total

Review 1.  The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development.

Authors:  Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-05       Impact factor: 3.978

Review 2.  Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Suvi Häkkinen; Stephanie A Chu; Suzee E Lee
Journal:  Neurobiol Dis       Date:  2020-09-02       Impact factor: 5.996

3.  Progranulin: Functions and neurologic correlations.

Authors:  Ryan A Townley; Bradley F Boeve; Eduardo E Benarroch
Journal:  Neurology       Date:  2017-12-20       Impact factor: 9.910

4.  2016 in Review and Message from the Editors to our Reviewers.

Authors:  Stefan M Pulst; Nicholas Elwood Johnson; Alexandra Durr; Massimo Pandolfo; Raymond P Roos; Jeffery M Vance
Journal:  Neurol Genet       Date:  2017-02-15

5.  Gray matter changes in asymptomatic C9orf72 and GRN mutation carriers.

Authors:  Karteek Popuri; Emma Dowds; Mirza Faisal Beg; Rakesh Balachandar; Mahadev Bhalla; Claudia Jacova; Adrienne Buller; Penny Slack; Pheth Sengdy; Rosa Rademakers; Dana Wittenberg; Howard H Feldman; Ian R Mackenzie; Ging-Yuek R Hsiung
Journal:  Neuroimage Clin       Date:  2018-02-17       Impact factor: 4.881

6.  Pathological correlates of white matter hyperintensities in a case of progranulin mutation associated frontotemporal dementia.

Authors:  Ione O C Woollacott; Martina Bocchetta; Carole H Sudre; Basil H Ridha; Catherine Strand; Robert Courtney; Sebastien Ourselin; M Jorge Cardoso; Jason D Warren; Martin N Rossor; Tamas Revesz; Nick C Fox; Janice L Holton; Tammaryn Lashley; Jonathan D Rohrer
Journal:  Neurocase       Date:  2018-08-16       Impact factor: 0.881

Review 7.  The Role of Microglia in Inherited White-Matter Disorders and Connections to Frontotemporal Dementia.

Authors:  Daniel W Sirkis; Luke W Bonham; Jennifer S Yokoyama
Journal:  Appl Clin Genet       Date:  2021-03-31

8.  Genetics of neurodegenerative diseases.

Authors:  Stefan M Pulst
Journal:  Neurol Genet       Date:  2016-02-18

9.  Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: A cross-sectional diffusion tensor imaging study.

Authors:  Lize C Jiskoot; Martina Bocchetta; Jennifer M Nicholas; David M Cash; David Thomas; Marc Modat; Sebastien Ourselin; Serge A R B Rombouts; Elise G P Dopper; Lieke H Meeter; Jessica L Panman; Rick van Minkelen; Emma L van der Ende; Laura Donker Kaat; Yolande A L Pijnenburg; Barbara Borroni; Daniela Galimberti; Mario Masellis; Maria Carmela Tartaglia; James Rowe; Caroline Graff; Fabrizio Tagliavini; Giovanni B Frisoni; Robert Laforce; Elizabeth Finger; Alexandre de Mendonça; Sandro Sorbi; Janne M Papma; John C van Swieten; Jonathan D Rohrer
Journal:  Ann Clin Transl Neurol       Date:  2018-07-11       Impact factor: 4.511

10.  White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study.

Authors:  Carole H Sudre; Martina Bocchetta; Carolin Heller; Rhian Convery; Mollie Neason; Katrina M Moore; David M Cash; David L Thomas; Ione O C Woollacott; Martha Foiani; Amanda Heslegrave; Rachelle Shafei; Caroline Greaves; John van Swieten; Fermin Moreno; Raquel Sanchez-Valle; Barbara Borroni; Robert Laforce; Mario Masellis; Maria Carmela Tartaglia; Caroline Graff; Daniela Galimberti; James B Rowe; Elizabeth Finger; Matthis Synofzik; Rik Vandenberghe; Alexandre de Mendonça; Fabrizio Tagliavini; Isabel Santana; Simon Ducharme; Chris Butler; Alex Gerhard; Johannes Levin; Adrian Danek; Giovanni B Frisoni; Sandro Sorbi; Markus Otto; Henrik Zetterberg; Sebastien Ourselin; M Jorge Cardoso; Jonathan D Rohrer
Journal:  Neuroimage Clin       Date:  2019-11-06       Impact factor: 4.881

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.